INFECTOPHARM Arzneimittel und Consilium GmbH is a family-owned company specializing in the development and distribution of pharmaceuticals for children, as well as products for infectious diseases, pulmonology, dermatology, and ENT. The product portfolio includes prescription and over-the-counter drugs, medical devices, cosmetics, and food supplements. Instead of a traditional pharmaceutical sales force, the company relies on a certified consulting and training offering for medical professionals under the brands consilium and PaediaAkademie. The primary sales market is Germany, accounting for approximately 75% of revenue, while international business, particularly in Europe, is growing disproportionately.
Die Herstellung und der Vertrieb von Arzneimitteln sowie die Vermittlung von medizinischen Fach- und Sachinformationen (Consilium) in Bezug auf Arzneimittel.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Darmstadt Local Court, HRB 24623 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Aldo Ammendola | Geschäftsführer(in) | Gräfelfing |
| Michael Gilster | Geschäftsführer(in) | Ludwigshafen |
| Markus Rudolph | Geschäftsführer(in) | Heppenheim |
| Philipp Zöller | Geschäftsführer(in) | Darmstadt |
| Company | Location |
|---|---|
| Heppenheim | |
| Berlin |
Source: German Commercial Register (Handelsregister) Darmstadt Local Court, HRB 24623 (as of 30 October 2026)
| Date | Contract | Value |
|---|---|---|
| 5.8.2025 | Supplier · DAK-Gesundheit | — |
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2022 | €250,877,022 | €63,875,043 | €430,943,557 | 395 |
| 2021 | €214,200,549 | €57,874,798 | €388,804,728 | 354 |
| 2020 | €184,593,840 | €54,943,752 | €367,574,779 | 219 |
| 2019 | €174,534,991 | €52,725,794 | €259,047,179 | 211 |
| 2018 | €138,027,511 | €41,249,933 | €208,643,746 | 194 |
| 2017 | €121,362,663 | €35,568,872 | €158,999,539 | 183 |
| 2016 | €105,861,075 | €32,625,574 | €176,902,377 | 183 |
| 2015 | €93,361,107 | €25,476,304 | €152,700,765 | 179 |
| 2014 | €79,378,660 | €18,587,520 | €126,604,019 | 171 |
| 2013 | €74,533,935 | €17,223,150 | €110,715,203 | 161 |
Sign in to download data
Source: German Commercial Register (Handelsregister) Darmstadt Local Court, HRB 24623 (as of 30 October 2026)
LTS LOHMANN Therapie-Systeme AG.
Andernach · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
WuXi Biologics Germany GmbH
Leverkusen · Herstellung von pharmazeutischen Grundstoffen
mibe GmbH Arzneimittel
Sandersdorf-Brehna · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €28,420,904 | 22.1% |
| Material Costs | €79,002,946 | 61.4% |
| Depreciation | €21,087,176 | 16.4% |
| Interest & Similar | €220,967 | 0.2% |